



Universiteit  
Leiden  
The Netherlands

## Targeted therapy for triple-negative breast cancer

McLaughlin, R.P.

### Citation

McLaughlin, R. P. (2018, December 13). *Targeted therapy for triple-negative breast cancer*. Retrieved from <https://hdl.handle.net/1887/68194>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/68194>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/68194> holds various files of this Leiden University dissertation.

**Author:** McLaughlin, R.P.

**Title:** Targeted therapy for triple-negative breast cancer

**Issue Date:** 2018-12-13

# Targeted Therapy for Triple-Negative Breast Cancer

Ronan Patrick McLaughlin

# Targeted Therapy for Triple-Negative Breast Cancer

PROEFSCHRIFT

ter verkrijging van de graad van Doctor aan de Universiteit Leiden,

op gezag van Rector Magnificus, Prof. mr. C.J.J.M. Stolker

volgens besluit van het College voor Promoties

te verdedigen op 13-12-2018

klokke 12:30 uur

door

Ronan Patrick McLaughlin

geboren op 11 juli 1990 te Edinburgh, Schotland (Verenigd Koninkrijk)

## **Promotor**

*Prof. Dr. Bob Van de Water (Drug Discovery & Safety; LACDR, Universiteit Leiden)*

## **Co-Promotor**

*Dr. Yinghui Zhang (Drug Discovery & Safety; LACDR, Universiteit Leiden)*

## **Promotion committee**

*Prof. Dr. Hubertus Irth (Scientific Director, LACDR, Universiteit Leiden, Voorzitter)*

*Prof. Dr. Joke Bouwstra (Biotherapeutics, LACDR, Universiteit Leiden, Secretaris)*

*Prof. Dr. Ad. IJzerman (Drug Discovery & Safety; LACDR, Universiteit Leiden)*

*Prof. Dr. John Martens (Medical Oncology; Erasmus MC Rotterdam)*

*Prof. Dr. Peter Devilee (Human Genetics, LUMC)*

© 2018 Ronan Patrick McLaughlin. All rights reserved.

Cover By: Adapted from [www.publicdomainpictures.net/en/view-image.php?image=42719&picture=cell](http://www.publicdomainpictures.net/en/view-image.php?image=42719&picture=cell) (under CC0 license) by Ronan Patrick McLaughlin. 2018.

ISBN: 978-94-6361-205-0

An electronic version of this thesis can be found at <https://openaccess.leidenuniv.nl>

Printed by: Optima Grafische Communicatie B.V. Rotterdam

This research was conducted at the Division of Drug Discovery and Safety of the Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.

## **Table of Contents**

<b>Chapter 1</b>	<b>1</b>
Introduction, Aim and Outline of this Thesis	
<b>Chapter 2</b>	<b>55</b>
A cell cycle gene signature is associated with resistance to MEK and Akt inhibitors in triple-negative breast cancer	
<b>Chapter 3</b>	<b>100</b>
Blockage of cdc7/CDK9 signalling sensitises triple-negative breast cancer to EGFR-targeted therapy	
<b>Chapter 4</b>	<b>139</b>
Targeting the P-TEFb complex through CDK9 inhibition to combat triple-negative breast cancer	
<b>Chapter 5</b>	<b>183</b>
The synergistic effect of combined P-TEFb and EGFR inhibition on triple-negative breast cancer	
<b>Chapter 6</b>	<b>216</b>
Discussion & Future Perspectives	
<b>Appendix</b>	<b>238</b>
<b>Summary (English)</b>	<b>239</b>
<b>Resumen (Español)</b>	<b>244</b>
<b>Nederlandse samenvatting</b>	<b>249</b>
<b>List of Publications</b>	<b>254</b>
<b>Curriculum Vitae</b>	<b>255</b>
<b>Acknowledgements</b>	<b>256</b>